A
weekly e-journal by Art Epstein, OD, FAAO
I get a real hoot out of some the letters we receive from family and friends this
time of year. In that spirit, I thought I would share an Optometric Physician holiday letter with you.
|
|||||
|
|
Pigment Deposition of Cosmetic Contact Lenses on the Cornea After Intense Pulsed-Light Treatment | ||||
A 30-year-old female presented with ocular pain and epiphora in both eyes.
These symptoms developed after she had undergone facial intense pulsed-light (IPL) treatment.
She was wearing cosmetic contact lenses throughout the IPL procedure.
At presentation, her uncorrected visual acuity was 20/200 in both eyes, and the slit-lamp examination revealed deposition of the color pigment of the cosmetic contact lens onto the corneal epithelium. The corneal epithelium was scraped using a no. 15 blade. Seven days after the procedure, the corneal epithelium had healed without any complications. This case highlights the importance of considering the possibility of ocular complications during IPL treatment, particularly in individuals using contact lenses. To prevent ocular damage, IPL procedures should be performed only after removing the lenses and applying eyeshields. |
||||
SOURCE: Hong S, Lee JR, Lim T. Pigment deposition of cosmetic contact lenses on the cornea after intense pulsed-light treatment. Korean J Ophthalmol 2010;24(6):367–70. |
Acupuncture Reduces Symptoms of Dry Eye Syndrome | ||||
The aim of this study was to evaluate the effect of acupuncture treatment on dry
eye syndrome. This was a prospective observational study conducted at a clinical evaluation center
for acupuncture and moxibustion of the Korean Institute of Oriental Medicine. The subjects were
patients with dry eye disease (n = 36), defined by Schirmer test scores of <10 mm/5 min and
tear film break-up times (BUTs) of <10 seconds. Participants were treated with acupuncture
three times per week for four weeks. Schirmer test scores, BUTs, symptom scores, ocular surface
disease index (OSDI) scores and dry eye symptom questionnaires were compared before and after
treatment to evaluate the efficacy of acupuncture treatment.
After treatment, symptom scores, OSDI scores and the number of dry eye symptoms were all significantly lower. Although tear wettings were significantly higher, there were no significant differences in BUTs. This study suggests that acupuncture treatment can effectively relieve the symptoms of dry eye and increase watery secretion. |
||||
SOURCE: Jeon JH, Shin MS, Lee MS, et al. Acupuncture reduces symptoms of dry eye syndrome: a preliminary observational study. J Altern Complement Med 2010;16(12):1291–1294. |
Characterization of Peripapillary Atrophy Using Spectral Domain Optical Coherence Tomography | ||||
Spectral domain optical coherence tomography (SD-OCT) imaging of the optic disc
was performed on healthy eyes, eyes suspected of having glaucoma and eyes diagnosed with glaucoma
to characterize peripapillary atrophy (PPA) zones in glaucomatous eyes. From the
peripheral β-zone, the retinal nerve fiber layer (RNFL), the junction of the inner and
outer segments (IS/OS) of the photoreceptor layer, and the Bruch's membrane/retinal
pigment epithelium complex layer (BRL) were visualized.
Nineteen consecutive eyes of ten subjects were imaged. The RNFL was observed in the PPA β-zone of all eyes, and no eye showed an IS/OS complex in the β-zone. The BRL was absent in the β-zone of two eyes. The BRL was incomplete or showed posterior bowing in the β-zone of five eyes. The common findings in the PPA β-zone were that the RNFL was present, but the photoreceptor layer was absent. Presence of the BRL was variable in the β-zone areas. |
||||
SOURCE: Na JH, Moon BG, Sung KR, Lee Y, Kook MS. Characterization of peripapillary atrophy using spectral domain optical coherence tomography. Korean J Ophthalmol 2010;24(6):353–359. |
|
News & Notes | ||
ALCON-NOVARTIS MERGER OFFERS EXPANDED OPPORTUNITIES.
In a recent
press release, Alcon, Inc. announced that its board of
directors approved a merger agreement with Novartis AG, whereby Novartis will pay a total
merger consideration valued at $168 per share for the Alcon shares it does not currently own.
The merger, which is expected to be completed during the first half of 2011, will be effected under Swiss merger law and is conditional, among other things, on two-thirds approval by the shareholders of both Novartis and Alcon voting at their respective meetings. Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment. According to Alcon, the new eye care division will combine the company's in-depth scientific knowledge of eye disease and clinical experience with the broad-based research capabilities and resources of Novartis, allowing for an expanded commitment to research and development activities in eye care. |
||
NEW COMPACT GONIO LENS FROM VOLK. Now available is Volk Optical's new Mini 4 Mirror Gonio Lens, which, according to Volk, delivers complete angle views. The Mini 4 Mirror offers a full view of the chamber angle at 1.0x magnification with a slight lens rotation and the small body and ring make for easy manipulation of the lens, especially within a small orbit. The company says that its newest lens is an excellent complement to a standard 4 mirror Gonio lens, offering additional flexibility with a smaller body. For more information, visit www.volk.com. | ||
SANTEN LAUNCHES NEW DRY EYE TREATMENT IN JAPAN. Santen Pharmaceutical Co., Ltd. has launched its new dry eye treatment, DIQUAS Ophthalmic Solution 3% (diquafosol sodium) in Japan. The drug has a new mechanism of action for dry eye that was licensed for certain ophthalmic uses from Inspire Pharmaceuticals, Inc. and developed by Santen. Clinical studies conducted in Japan showed that DIQUAS improved dry eye symptoms by promoting secretion of mucin and water as main components of tears, thereby bringing the tear film closer to a normal state. No serious ocular or systemic adverse drug reactions were found during the clinical trials. Read more here. | ||
|
HOW TO SUBMIT NEWS
HOW TO ADVERTISE
|